BR112018013805A2 - métodos e dispositivos para o tratamento de distúrbio ocular posterior com aflibercept e outros produtos biológicos - Google Patents
métodos e dispositivos para o tratamento de distúrbio ocular posterior com aflibercept e outros produtos biológicosInfo
- Publication number
- BR112018013805A2 BR112018013805A2 BR112018013805-3A BR112018013805A BR112018013805A2 BR 112018013805 A2 BR112018013805 A2 BR 112018013805A2 BR 112018013805 A BR112018013805 A BR 112018013805A BR 112018013805 A2 BR112018013805 A2 BR 112018013805A2
- Authority
- BR
- Brazil
- Prior art keywords
- devices
- medicament container
- methods
- aflibercept
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção está relacionada aos métodos e dispositivos para o tratamento de amd úmida, cnv, amd úmida associada com cnv e/ou amd úmida associada com rvo em um indivíduo humano necessitado. em certos aspectos, os dispositivos fornecidos nesse relatório descritivo incluem um recipiente de medicamento que define um lúmen configurado para conter um medicamento, uma porção da extremidade distal do recipiente de medicamento que inclui uma porção de acoplamento configurada para ser acoplada de forma removível a um conjunto de agulhas, uma porção da extremidade proximal do recipiente de medicamento que inclui um flange e um rebordo longitudinal; um conjunto de pistão que inclui uma porção da extremidade distal disposta de forma móvel dentro do lúmen do recipiente de medicamento; e um cabo acoplado a uma porção da extremidade proximal do conjunto de pistão.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662276543P | 2016-01-08 | 2016-01-08 | |
US62/276,543 | 2016-01-08 | ||
US201662324708P | 2016-04-19 | 2016-04-19 | |
US62/324,708 | 2016-04-19 | ||
PCT/US2017/012757 WO2017120601A1 (en) | 2016-01-08 | 2017-01-09 | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018013805A2 true BR112018013805A2 (pt) | 2018-12-11 |
Family
ID=59274052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018013805-3A BR112018013805A2 (pt) | 2016-01-08 | 2017-01-09 | métodos e dispositivos para o tratamento de distúrbio ocular posterior com aflibercept e outros produtos biológicos |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3400014A1 (pt) |
JP (1) | JP2019501200A (pt) |
KR (1) | KR20180101488A (pt) |
CN (1) | CN108778330A (pt) |
AU (1) | AU2017206114A1 (pt) |
BR (1) | BR112018013805A2 (pt) |
CA (1) | CA3010862A1 (pt) |
MX (1) | MX2018008469A (pt) |
WO (1) | WO2017120601A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
EP3520749A1 (en) | 2010-10-15 | 2019-08-07 | Clearside Biomedical, Inc. | Device for ocular access |
MX2015005839A (es) | 2012-11-08 | 2015-12-17 | Clearside Biomedical Inc | Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
AU2014259694B2 (en) | 2013-05-03 | 2018-11-08 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
WO2014197317A1 (en) | 2013-06-03 | 2014-12-11 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
WO2015011199A1 (en) | 2013-07-23 | 2015-01-29 | Novaliq Gmbh | Stabilized antibody compositions |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
WO2017117464A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
SG11201808426XA (en) | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
JP2019514581A (ja) | 2016-05-02 | 2019-06-06 | クリアサイド バイオメディカル,インコーポレイテッド | 眼の薬物送達のためのシステムおよび方法 |
EP3496680A1 (en) | 2016-08-12 | 2019-06-19 | Clearside Biomedical, Inc. | Devices and methods for adjusting the insertion depth of a needle for medicament delivery |
AU2018342094A1 (en) * | 2017-09-27 | 2020-04-02 | Regenxbio Inc. | Treatment of ocular diseases with fully-human post-translationally modified anti-VEGF Fab |
SG11202005719UA (en) * | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
CN108030783A (zh) * | 2017-12-27 | 2018-05-15 | 广东众生药业股份有限公司 | 乐伐替尼在制备防治黄斑变性的药物中的用途 |
WO2019217927A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
CN110693886B (zh) * | 2018-07-09 | 2022-12-06 | 天津医科大学 | 防治脑海绵状血管畸形病变的药物 |
KR20200101160A (ko) * | 2019-02-19 | 2020-08-27 | 전남대학교산학협력단 | 리보세라닙을 포함하는 안구 신생혈관 억제용 약학 조성물 및 이를 이용한 안구 신생혈관 억제 방법 |
EP3946467A1 (en) * | 2019-04-03 | 2022-02-09 | REGENXBIO Inc. | Gene therapy for eye pathologies |
CN110522909B (zh) * | 2019-09-30 | 2024-02-20 | 安徽省立医院 | 一种协同增强抗her2阳性肿瘤效果的药物组合 |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
AU2020383580A1 (en) * | 2019-11-11 | 2022-05-12 | Cstone Pharmaceuticals | Pharmaceutical combination and use thereof |
EP4106755A4 (en) * | 2020-02-19 | 2024-03-27 | Clearside Biomedical Inc | COMPOSITIONS CONTAINING AXITINIB AND METHODS FOR TREATING OCULAR DISEASES |
EP4164593A1 (en) * | 2020-06-15 | 2023-04-19 | OPKO Pharmaceuticals, LLC | Triamcinolone acetonide-loaded liposomes topical ophthalmic formulations as primary therapy for macular edema secondary to branch retinal vein occlusion |
TW202313095A (zh) * | 2021-05-17 | 2023-04-01 | 美商再生元醫藥公司 | 用於治療血管新生眼疾之延長、高劑量vegf拮抗劑方案 |
CN113546176B (zh) * | 2021-06-30 | 2024-03-15 | 南通大学 | 一种特异性用于抑制眼内血管新生药物合成方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2714734A1 (en) * | 2011-05-27 | 2014-04-09 | Novartis AG | Method of treating vision disorders |
WO2013126799A1 (en) * | 2012-02-22 | 2013-08-29 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
MX2015005839A (es) * | 2012-11-08 | 2015-12-17 | Clearside Biomedical Inc | Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
US20160310417A1 (en) * | 2013-12-20 | 2016-10-27 | Emory University | Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents |
CA2952822A1 (en) * | 2014-06-17 | 2015-12-23 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorders |
-
2017
- 2017-01-09 EP EP17736528.5A patent/EP3400014A1/en not_active Withdrawn
- 2017-01-09 BR BR112018013805-3A patent/BR112018013805A2/pt not_active Application Discontinuation
- 2017-01-09 CN CN201780015406.9A patent/CN108778330A/zh active Pending
- 2017-01-09 MX MX2018008469A patent/MX2018008469A/es unknown
- 2017-01-09 KR KR1020187022893A patent/KR20180101488A/ko unknown
- 2017-01-09 WO PCT/US2017/012757 patent/WO2017120601A1/en active Application Filing
- 2017-01-09 AU AU2017206114A patent/AU2017206114A1/en not_active Abandoned
- 2017-01-09 CA CA3010862A patent/CA3010862A1/en not_active Abandoned
- 2017-01-09 JP JP2018535400A patent/JP2019501200A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3400014A1 (en) | 2018-11-14 |
CA3010862A1 (en) | 2017-07-13 |
WO2017120601A1 (en) | 2017-07-13 |
KR20180101488A (ko) | 2018-09-12 |
AU2017206114A1 (en) | 2018-08-02 |
JP2019501200A (ja) | 2019-01-17 |
MX2018008469A (es) | 2018-11-09 |
CN108778330A (zh) | 2018-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018013805A2 (pt) | métodos e dispositivos para o tratamento de distúrbio ocular posterior com aflibercept e outros produtos biológicos | |
MX2016016836A (es) | Metodos y dispositivos para tratar trastornos oculares posteriores. | |
CL2017001117A1 (es) | Métodos para tratar enfermedades oculares. | |
BR112017009807A2 (pt) | métodos e formulações para tratamento de doenças oculares vasculares | |
MX2021013560A (es) | Dispositivo de asistencia quirurgica. | |
BR112014010020A2 (pt) | enxerto para elevação de tecido que é inserido entre a pele flácida ou enrugada e o músculo subcutâneo para permitir o puxamento e/ou o alisamento de tecido | |
BR112016000546A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
BR112015006623A2 (pt) | laquinimod e pridopidina para o tratamento de doenças neurodegenerativas | |
BR112017016759A2 (pt) | recipiente de plástico pré-carregado, kit, uso do recipiente de plástico pré-carregado, método para o tratamento de uma doença ou condição, método para o tratamento cosmético da pele | |
BR112017020132A2 (pt) | métodos para promover o crescimento capilar ou prevenir a perda de cabelo em um indivíduo e para preparar uma composição, e, composição | |
CL2019001951A1 (es) | Composición aceite en agua de silicona útil como un relleno inyectable y como andamio para el crecimiento de colágeno. | |
CO6500125A1 (es) | Suministro de curcumina por derivacion | |
WO2016164349A3 (en) | Implantable fluid delivery system | |
WO2015138773A3 (en) | Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances | |
EP4295906A3 (en) | Treatment of restenosis using temsirolimus | |
WO2016074040A3 (en) | Non-invasive agent applicator | |
WO2016060917A3 (en) | Formulations for histatin therapeutics | |
BR112018012765A2 (pt) | composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico. | |
NZ729181A (en) | Treatment of disease with poly-n-acetylglucosamine nanofibers | |
MX2016008818A (es) | Dispositivo y metodo para uso de la terapia fotodinamica. | |
MX2020006473A (es) | Uso de hm4di en el tratamiento de trastornos convulsivos. | |
BR112018014964A2 (pt) | células multipotentes e tecido microvascular melhorados e métodos de uso dos mesmos | |
Codeluppi et al. | Optic nerve involvement in retinal migraine. | |
IL282898A (en) | Ophthalmic compounds and methods for treating skin and eye diseases | |
Tarutta et al. | A new way of diagnostic and treatment effectiveness evaluation of the optical nystagmus using microperimetry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |